Global Calcineurin Inhibitors Market Size study, By Diseases (Atopic Dermatitis, Postoperative Immunosuppression, Ulcerative Colitis, Psoriasis, Keratoconjunctivitis, Others), Drug (Cyclosporine, Tacrolimus, Pimecrolimus, Others), Route of Administration

Global Calcineurin Inhibitors Market Size study, By Diseases (Atopic Dermatitis, Postoperative Immunosuppression, Ulcerative Colitis, Psoriasis, Keratoconjunctivitis, Others), Drug (Cyclosporine, Tacrolimus, Pimecrolimus, Others), Route of Administration (Oral, Topical, Parenteral), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), and Regional Forecasts 2022-2028

Global Calcineurin Inhibitors Market is valued approximately USD XX million in 2021 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2022-2028. Calcineurin Inhibitors can be defined as immunosuppressants (drugs or medicines that lower the body's ability to reject a transplanted organ) used to manage autoimmune conditions such as lupus nephritis, idiopathic inflammatory myositis, interstitial lung disease, atopic and dermatitis among others. Growing prevalence of prevalence of psoriasis and increasing cases of organ transplant as well as recent product launches from leading market players are key drivers for growth of Calcineurin Inhibitors Market. For instance, according to Global Psoriasis Atlas - as of 2021, around 60 million people are suffering from psoriasis worldwide. Furthermore, in USA around 3.65 million people are affected with psoriasis, whereas in UK around 1.01 million have psoriasis. Moreover, in December 2020, Biopharmaceuticals company Biocon launched Tacrolimus capsules in the US. Tacrolimus, a calcineurin inhibitor, is an immunosuppressant used in the treatment of organ transplant patients. Also, growing number of research and development activities and rising healthcare infrastructure in emerging economies are anticipated to act as a catalyzing factor for the market demand during the forecast period. However, side effects associated with calcineurin inhibitors impede the growth of the market over the forecast period of 2022-2028.

The key regions considered for the global Calcineurin Inhibitors Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to rising R&D activities and increasing prevalence of atopic dermatitis as well as presence of leading market players. Whereas, Asia Pacific is anticipated to exhibit a significant growth rate over the forecast period 2022-2028. Factors such as growing healthcare sector and increasing penetration of global pharmaceuticals companies in the region, would create lucrative growth prospects for the Calcineurin Inhibitors Market across the Asia Pacific region.

Major market players included in this report are:
F. Hoffmann-La Roche Ltd. (Switzerland)
Mylan N.V. (U.S.)
Teva Pharmaceutical Industries Ltd.(Israel)
Sanofi (France)
Pfizer Inc. (U.S.)
GlaxoSmithKline plc (U.K.)
Novartis AG (Switzerland)
AstraZeneca (U.K.)
Johnson & Johnson (U.S.)
Bayer AG (Germany)


The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Diseases
Atopic Dermatitis
Postoperative Immunosuppression
Ulcerative Colitis
Psoriasis
Keratoconjunctivitis
Others
By Drug
Cyclosporine
Tacrolimus
Pimecrolimus
Others
By Route of Administration
Oral
Topical
Parenteral
By End-Users
Hospitals
Specialty Clinics
Homecare
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global Calcineurin Inhibitors Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

Companies Mentioned

F. Hoffmann-La Roche Ltd. (Switzerland)
Mylan N.V. (U.S.)
Teva Pharmaceutical Industries Ltd.(Israel)
Sanofi (France)
Pfizer Inc. (U.S.)
GlaxoSmithKline plc (U.K.)
Novartis AG (Switzerland)
AstraZeneca (U.K.)
Johnson & Johnson (U.S.)
Bayer AG (Germany)

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.